Product
Oxacillin
1 clinical trial
1 indication
Indication
Staphylococcal BacteraemiaClinical trial
Dalbavancin as an Option for Treatment of S. Aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated S. Aureus BacteremiaStatus: Completed, Estimated PCD: 2023-10-06